Ariel Pharmaceuticals in-licenses AP-1531 from BTG for acute migraine attacks Ariel Pharmaceuticals, Inc., a private, specialty pharmaceutical company focused on the development and commercialization of items for acute central anxious system diseases and trauma, today that it has in-licensed its lead item announced, AP-1531, for the treatment of acute migraine attacks, from the specialist healthcare firm BTG International Ltd . While the precise reason behind migraines is not fully understood, adjustments in vascular tone and inflammatory processes look like key contributing factors. .BioMarin Pharmaceutical Inc.U.) for the treating the uncommon autoimmune disease Lambert Eaton Myasthenic Syndrome .U. In December 2009 and may be the first approved treatment because of this indication for the treating LEMS, thereby conferring orphan medication protection and providing a decade of marketplace exclusivity in European countries. Related StoriesRaising lupus consciousness: an interview with Professor Ramsey-Goldman, MDPhenotyping human illnesses in mice: an interview with Professor Carola Vinuesa The start of Firdapse brings the 1st specifically approved treatment choice for LEMS to sufferers in the E.U.